在基于T细胞的采用性免疫疗法中,在体外扩张过程中生成的非典型T细胞的表征
Patricia Mercier-Letondal1, Abhishek Kumar1, Chrystel Marton2
1UMR 1098 RIGHT INSERM, Etablissement Français du Sang Bourgogne Franche-Comté, Université de Franche-Comté, Besançon, France.
Frontiers in immunology
|March 28, 2024
概括
在工程T细胞治疗中研究非典型的T细胞子集揭示了不匹配的T细胞和细胞毒性CD4+T细胞可能会影响治疗疗效. 了解这些非典型细胞对于改善采用免疫疗法的结果至关重要.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞疗法细胞疗法
- 在瘤学瘤学.
背景情况:
- 工程T细胞免疫疗法对血液癌症有希望,但在固体瘤和复发管理方面面临挑战.
- 控制T细胞产品的特性对于分析临床试验和提高免疫疗法的疗效至关重要.
- 非典型的T细胞子集,包括不匹配或错误的T细胞,可能会影响治疗结果.
研究的目的:
- 在HPV16-E7特定的MHC II受限制的转基因T细胞环境中研究非典型T细胞子集的表型和功能特征.
- 了解不匹配的MHC/共受体和错误的T细胞对T细胞功能的影响.
- 探索白蛋白补充在T细胞表型发育中的作用.
主要方法:
- 在CD8和CD4T细胞上生成不匹配和适当匹配的MHC II受限转基因T细胞受体 (TCR).
- 分析T细胞子集的表型和功能特征,包括细胞毒性活动.
- 评估IL-2或IL-7/IL-15补充对T细胞表型的影响.
主要成果:
- 在体外培养的CD4+T细胞表现出错误的细胞毒性表型,该表型通过IL-2或IL-7/IL-15补充剂得到增强.
- 用HPV16-E7特异性TCR进行工程的CD4+和CD8+T细胞子集在暴露于抗原时表现出细胞毒性活性.
- 鉴定了非典型的T细胞,如不匹配的MHC II受限TCR/CD8+T细胞和细胞毒性CD4+T细胞.
结论:
- 非典型T细胞的存在,包括不匹配和错误的子集,可以显著影响基于T细胞的采用性免疫治疗的有效性.
- 对这些非典型的T细胞群体进行进一步的研究是必要的,以优化T细胞产品的质量,并改善癌症治疗的治疗结果.
- 了解和控制非典型的T细胞子集对于推进T细胞疗法至关重要,特别是在固体瘤中.
更多相关视频
07:20Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
14.7K
10:44A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants
Published on: August 9, 2019
7.2K
相关概念视频
T Cell Activation and Clonal Selection
721
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
721
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Tumor Immunotherapy
523
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523
Special Features of Adaptive Immunity
810
The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
810
